文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FAPI-04 PET/CT无创诊断与分类肾移植排斥反应

Noninvasive diagnosis and classification of kidney transplantation rejection by 18F-FAPI-04 PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-08

该前瞻性研究纳入24例肾移植受者,分为对照组与排斥组(再分急性、混合、慢性排斥亚组),均行18F-FAPI-04 PET/CT与18F-FDG PET/CT并对照FAP免疫组化与Banff病理评分。结果显示排斥组移植肾皮质和活检部位18F-FAPI-04 SUVmax显著高于对照组,且慢性排斥组中18F-FAPI-04在皮质、活检部位和髓质的SUVmax均显著高于18F-FDG。

要点

  • 排斥组移植肾皮质和活检部位18F-FAPI-04 SUVmax显著高于对照组。
  • 慢性排斥组中18F-FAPI-04在皮质、活检部位和髓质的SUVmax均显著高于18F-FDG。
  • 活检部位18F-FAPI-04 SUVmax在急性、混合、慢性排斥组间逐渐升高(2.8 vs 3.6 vs 5.3,p=0.02)。

核心结论

  • 18F-FAPI-04 PET/CT在区分肾移植排斥反应尤其是慢性排斥方面优于18F-FDG PET/CT。

研究设计与样本

  • 前瞻性纳入24例肾移植受者,分为对照组与排斥组(KTR),排斥组再分为急性排斥(AR)、混合排斥(MR)和慢性排斥(CR)亚组。
  • 所有患者均行18F-FAPI-04 PET/CT和18F-FDG PET/CT扫描,并接受FAP免疫组化染色和Banff病理评分。

主要发现

  • 与对照组相比,排斥组血清肌酐显著更高、估算肾小球滤过率更低、血红蛋白更低。
  • 排斥组移植肾皮质(AKC)和移植肾活检部位(AKB)的18F-FAPI-04 SUVmax显著高于对照组;18F-FDG PET/CT的SUVmax两组仅在AKC存在显著差异。
  • 排斥组中18F-FAPI-04在AKC和AKB的SUVmax显著高于18F-FDG(分别为5.5 vs 2.8和3.6 vs 2.5,均p<0.01)。
  • 慢性排斥组中18F-FAPI-04在AKC、AKB和移植肾髓质(AKM)的SUVmax分别为7.1、5.3和3.2,显著高于18F-FDG的2.5、2.1和1.8(p分别为0.009、0.009和0.016)。
  • 活检部位18F-FAPI-04 SUVmax在急性、混合、慢性排斥组间逐渐升高(2.8 vs 3.6 vs 5.3,p=0.02);上述结果与SUVavg统计一致;FAP阳性基质细胞数在对照组与排斥组间及AR、MR、CR亚组间存在差异。

关键数值与推荐

  • 排斥组18F-FAPI-04在AKC和AKB的SUVmax显著高于18F-FDG(5.5 vs 2.8和3.6 vs 2.5,均p<0.01)。
  • 慢性排斥组18F-FAPI-04在AKC、AKB、AKM的SUVmax分别为7.1、5.3、3.2,均显著高于18F-FDG的2.5、2.1、1.8(p=0.009、0.009、0.016)。
  • 活检部位18F-FAPI-04 SUVmax在AR、MR、CR组分别为2.8、3.6、5.3,组间比较p=0.02。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Rejection, especially chronic rejection is a key factor influencing the prognosis of kidney transplantation patients. While 18F-fibroblast activation protein inhibitor (FAPI)-04 PET/CT has been widely utilized for diagnosing various diseases, its diagnostic efficacy in kidney transplant rejection remains unexplored. METHODS: In this study, 24 kidney transplant recipients were prospectively enrolled and divided into a control cohort and a rejection cohort (KTR), which were further classified into acute rejection (AR), mixed rejection (MR), and chronic rejection (CR) subgroups. All patients underwent 18F-FAPI-04 PET/CT and 18F-FDG PET/CT scans, along with immunohistochemical FAP staining and Banff pathological scoring. The maximum and average standardized uptake values (SUVs) of the two imaging methods were calculated. RESULTS: Compared with the control cohort, the KTR cohort showed significantly higher serum creatinine levels, lower estimated glomerular filtration rates, and lower hemoglobin levels. The SUVmax of 18F-FAPI-04 PET/CT in the allograft kidney cortex (AKC) and allograft kidney biopsy site (AKB) in the KTR cohort was significantly greater than that in the control cohort. The SUVmax of 18F-FDG PET/CT between the two cohorts was significantly different only in the AKC. For the KTR cohort, the SUVmax of 18F-FAPI-04 PET/CT in AKC and AKB was considerably greater than that of 18F-FDG PET/CT (5.5 vs. 2.8 and 3.6 vs. 2.5, respectively; both p < 0.01). In the CR cohort, the SUVmax of 18F-FAPI-04 PET/CT in the AKC, AKB, and allograft kidney medulla (AKM) was significantly greater (7.1, 5.3, and 3.2) than that of 18F-FDG PET/CT (2.5, 2.1 and 1.8) (p = 0.009, 0.009 and 0.016, respectively). The SUVmax of 18F-FAPI-04 PET/CT in AKB increased gradually in the AR, MR, and CR cohorts (2.8 vs. 3.6 vs. 5.3, p = 0.02). The above results were consistent with the SUVavg statistics. The number of FAP-positive stromal cells was different between the control and KTR groups and among the AR, MR, and CR subgroups. CONCLUSION: 18F-FAPI-04 PET/CT outperforms 18F-FDG PET/CT in distinguishing kidney transplant rejection, especially chronic rejection.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Luo S, Xu M, Shen R, et al. Noninvasive diagnosis and classification of kidney transplantation rejection by 18F-FAPI-04 PET/CT. Eur J Nucl Med Mol Imaging. 2025. PMID: 40338305. doi:10.1007/s00259-025-07307-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。